What is HC Wainwright’s Estimate for Pharvaris Q4 Earnings?

Pharvaris N.V. (NASDAQ:PHVS) – HC Wainwright issued their Q4 2027 EPS estimates for Pharvaris in a research note issued to investors on Friday, August 14th. HC Wainwright analyst P. Trucchio expects that the company will post earnings of ($0.65) per share for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($3.15) per share. HC Wainwright also issued estimates for Pharvaris’ FY2030 earnings at $6.60 EPS.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06).

A number of other brokerages have also recently issued reports on PHVS. HSBC raised shares of Pharvaris to an “overweight” rating in a report on Thursday, August 13th. Citizens Jmp upped their target price on Pharvaris from $74.00 to $75.00 and gave the company a “market outperform” rating in a report on Thursday, August 13th. Wells Fargo & Company initiated coverage on Pharvaris in a research report on Wednesday, July 15th. They set an “overweight” rating and a $55.00 price target on the stock. UBS Group set a $74.00 price target on Pharvaris in a report on Wednesday, May 13th. Finally, Guggenheim boosted their price objective on Pharvaris from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $51.08.

Pharvaris Stock Up 2.2%

Shares of NASDAQ:PHVS opened at $36.10 on Monday. Pharvaris has a fifty-two week low of $20.65 and a fifty-two week high of $36.93. The firm has a 50-day simple moving average of $33.88 and a 200 day simple moving average of $30.23. The company has a market cap of $2.36 billion, a PE ratio of -11.84 and a beta of -2.31.

Hedge Funds Weigh In On Pharvaris

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PHVS. venBio Partners LLC bought a new stake in Pharvaris during the 2nd quarter valued at $160,569,809,000. Wellington Management Group LLP bought a new position in shares of Pharvaris in the third quarter worth $43,282,000. 5AM Venture Management LLC bought a new position in shares of Pharvaris in the second quarter worth $27,581,008,000. Seven Fleet Capital Management LP acquired a new position in shares of Pharvaris during the second quarter valued at $26,782,245,000. Finally, Paradigm Biocapital Advisors LP increased its holdings in shares of Pharvaris by 72.7% during the third quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock valued at $45,796,000 after purchasing an additional 772,583 shares during the period.

Insider Activity

In other Pharvaris news, insider Anne Lesage sold 27,872 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $35.48, for a total transaction of $988,898.56. Following the completion of the transaction, the insider directly owned 58,750 shares of the company’s stock, valued at $2,084,450. The trade was a 32.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Berndt Modig sold 2,292 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $34.77, for a total transaction of $79,692.84. Following the transaction, the chief executive officer directly owned 130,625 shares of the company’s stock, valued at $4,541,831.25. The trade was a 1.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 148,322 shares of company stock valued at $5,091,407.

Pharvaris News Roundup

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Pharvaris. Its projections still anticipate a significant improvement in profitability over time, including positive earnings of $3.09 per share in fiscal 2029. HC Wainwright Predicts Pharvaris’ Q4 Earnings
• Neutral Sentiment: HC Wainwright issued estimates for Pharvaris’ upcoming quarters and future fiscal years, reflecting continued near-term losses as the company advances its development programs. The firm expects losses of $3.41 per share in fiscal 2026 and $3.30 per share in fiscal 2027, followed by a smaller $0.56-per-share loss in fiscal 2028.
• Negative Sentiment: HC Wainwright reduced its fiscal 2026 EPS forecast to a loss of $3.41 from $2.98, and cut its fiscal 2027 forecast to a loss of $3.30 from $2.41. It also lowered estimates for third-quarter 2026, fourth-quarter 2026, fiscal 2028 and fiscal 2029, indicating expectations for greater near-term cash burn and a slower path to profitability.
• Negative Sentiment: Chief Executive Officer Berndt Modig sold 2,292 PHVS shares for approximately $79,693 at an average price of $34.77. He retained 130,625 shares, so the transaction was relatively small, but insider selling can weigh modestly on investor sentiment. SEC insider ownership filing

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.